Denali Therapeutics Inc.
DNLINASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $3.44B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $13.75$27.30
- Volume (live)
- -
- Avg. volume (3M)
- 1.81M
Denali Therapeutics (DNLI) Stock Price & Financial Analysis
Denali Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $18.01 - $18.53 |
|---|---|
| 52-Week High | $27.30 |
| 52-Week Low | $13.75 |
| Open | $18.04 |
| Volume (last close) | 1.57M |
| Average Volume (3M) | 1.81M |
| Revenue (TTM) | 3.60M |
|---|---|
| Net Income (TTM) | -511.45M |
| Free Cash Flow (TTM) | -437.46M |
| EPS (TTM) | −$2.83 |
| Profit Margin | -14191.20% |
| Operating Margin | -15058.19% |
| Return on Equity (ROE) | -61.24% |
| Debt to Equity | 0.03 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 3.44B |
|---|---|
| Shares Outstanding | 187.31M |
| Price to Sales (P/S) | 953.20 |
| Price to Book (P/B) | 4.11 |
| EV/EBITDA | -6.52 |
| 50-Day MA | $22.11 |
|---|---|
| 200-Day MA | $21.14 |
| 1-Year Change | +9.69% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Denali Therapeutics at a Glance
As of the Oct 15, 2026 close, Denali Therapeutics (DNLI) has a market capitalization of $3.44B. The stock trades at 953.2× sales. Over the trailing twelve months it lost $511.45M on revenue of $3.60M and burned $437.46M of free cash flow.
As of its latest reported balance sheet, it holds $201.53M in cash and securities against $22.03M of debt, a net cash position of $179.50M.
Denali Therapeutics does not currently pay a dividend.
The share price is up 9.7% over the past year. At $18.34 (the Oct 15, 2026 close) it sits within its 52-week range of $13.75 to $27.30, below its 200-day moving average of $21.14.
Based on 12 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $36.11, 96.9% above the Oct 15, 2026 close.
Frequently Asked Questions About Denali Therapeutics
What is the current stock price for DNLI?
As of the Oct 15, 2026 close, DNLI stock trades at $18.34. The 52-week range is $13.75–$27.30, with a day range of $18.01–$18.53.
What is the P/E ratio for DNLI?
The P/E ratio (Price-to-Earnings) for DNLI is shown in the Key Statistics section. This valuation metric helps compare Denali Therapeutics Inc. to industry peers.
Does DNLI pay dividends?
Denali Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for DNLI?
Based on ratings from 12 professional analysts over the last 90 days, the consensus for DNLI is Buy. The average 12-month price target is $36.11, a 96.9% upside from the Oct 15, 2026 close of $18.34.
What is the market cap of DNLI?
As of the Oct 15, 2026 close, Denali Therapeutics's market capitalization is $3.44B, classifying it as a mid-cap company. Denali Therapeutics operates in the Healthcare sector within the Biotechnology industry.